REVELATION BIOSCIENCES, INC. Research and Development Expense
REVELATION BIOSCIENCES, INC. (REVB) reported Research and Development Expense of $1.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- REVELATION BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $1.92M, a 45.56% increase year-over-year.
- REVELATION BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $1.38M, a 60.32% increase year-over-year.
- REVELATION BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $964.19K, a 59.24% increase year-over-year.
- REVELATION BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $922.86K, a 11.06% increase year-over-year.
- REVELATION BIOSCIENCES, INC. research and development expense for fiscal 2025 was $4.06M, a 14.51% increase from fiscal 2024.
- REVELATION BIOSCIENCES, INC. research and development expense for fiscal 2024 was $3.55M, a 14.40% decline from fiscal 2023.
- REVELATION BIOSCIENCES, INC. research and development expense for fiscal 2023 was $4.15M, a 22.90% decline from fiscal 2022.
- REVELATION BIOSCIENCES, INC. research and development expense for fiscal 2022 was $5.38M, a 22.23% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.92M 10-Q · filed 2026-08-06 | $3.30M 10-Q · filed 2026-08-06 | $4.26M derived: sum of 3 quarters · filed 2026-08-06 | $5.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.38M 10-Q · filed 2026-05-07 | $2.34M derived: sum of 2 quarters · filed 2026-05-07 | $3.26M derived: sum of 3 quarters · filed 2026-05-07 | $4.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $964.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.89M derived: sum of 2 quarters · filed 2026-02-26 | $3.21M derived: sum of 3 quarters · filed 2026-08-06 | $4.06M 10-K · filed 2026-02-26 |
| 2025-09-30 | $922.86K 10-Q · filed 2025-11-06 | $2.24M derived: sum of 2 quarters · filed 2026-08-06 | $3.10M 10-Q · filed 2025-11-06 | $3.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.32M 10-Q · filed 2026-08-06 | $2.18M 10-Q · filed 2026-08-06 | $2.78M derived: sum of 3 quarters · filed 2026-08-06 | $3.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $858.83K 10-Q · filed 2026-05-07 | $1.46M derived: sum of 2 quarters · filed 2026-05-07 | $2.30M derived: sum of 3 quarters · filed 2026-05-07 | $3.69M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $605.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.44M derived: sum of 2 quarters · filed 2026-02-26 | $2.83M derived: sum of 3 quarters · filed 2026-02-26 | $3.55M 10-K · filed 2026-02-26 |
| 2024-09-30 | $830.98K 10-Q · filed 2025-11-06 | $2.23M derived: sum of 2 quarters · filed 2025-11-06 | $2.94M 10-Q · filed 2025-11-06 | $4.00M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.39M 10-Q · filed 2025-08-08 | $2.11M 10-Q · filed 2025-08-08 | $3.17M derived: sum of 3 quarters · filed 2025-08-08 | $4.82M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $717.58K 10-Q · filed 2025-05-08 | $1.78M derived: sum of 2 quarters · filed 2025-05-08 | $3.43M derived: sum of 3 quarters · filed 2025-05-08 | $4.34M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.71M derived: sum of 2 quarters · filed 2025-03-06 | $3.62M derived: sum of 3 quarters · filed 2025-03-06 | $4.15M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.65M 10-Q · filed 2024-11-08 | $2.56M derived: sum of 2 quarters · filed 2024-11-08 | $3.09M 10-Q · filed 2024-11-08 | $3.43M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $909.28K 10-Q/A · filed 2024-09-23 | $1.43M 10-Q/A · filed 2024-09-23 | $1.77M derived: sum of 3 quarters · filed 2024-09-23 | $2.16M derived: sum of 4 quarters · filed 2024-09-23 |
| 2023-03-31 | $525.27K 10-Q/A · filed 2024-09-23 | $865.24K derived: sum of 2 quarters · filed 2024-09-23 | $1.25M derived: sum of 3 quarters · filed 2024-09-23 | $2.22M derived: sum of 4 quarters · filed 2024-09-23 |
| 2022-12-31 | $339.97K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-23 | $721.54K derived: sum of 2 quarters · filed 2024-09-23 | $1.70M derived: sum of 3 quarters · filed 2024-09-23 | $5.38M 10-K/A · filed 2024-09-23 |
| 2022-09-30 | $381.57K 10-Q · filed 2023-11-09 | $1.36M derived: sum of 2 quarters · filed 2023-11-09 | $5.04M 10-Q · filed 2023-11-09 | $7.70M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $975.58K 10-Q · filed 2023-08-11 | $4.66M 10-Q · filed 2023-08-11 | $7.32M derived: sum of 3 quarters · filed 2023-08-11 | $8.85M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $3.68M 10-Q · filed 2023-05-22 | $6.35M derived: sum of 2 quarters · filed 2023-05-22 | $7.88M derived: sum of 3 quarters · filed 2023-05-22 | $9.04M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.20M derived: sum of 2 quarters · filed 2023-03-30 | $5.36M derived: sum of 3 quarters · filed 2023-03-30 | $6.91M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.53M 10-Q · filed 2022-11-10 | $2.69M derived: sum of 2 quarters · filed 2022-11-10 | $4.25M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $1.16M 10-Q · filed 2022-08-15 | $2.72M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $1.56M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |